V-01 is a protein subunit COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc. __TOC__ == Preclinical studies ==
V-01 is a protein subunit COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc. __TOC__ == Preclinical studies ==
A preclinical study in rhesus macaques was published in July 2021. The vaccine's ability to neutralize several variants of concern has also been tested in mice. Another study in mice tested V-01 as a booster after inactivated Covid vaccine, including neutralization of a range of variants of concern.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).